Bladder Cancer | China In-Depth | China | 2021
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most robust drug-development pipelines in oncology. Notably, the biggest driver of market sales will be the anticipated approvals of immune checkpoint inhibitors from both multinational corporations and domestic companies; these agents will transform treatment. Biomarker-driven therapies are becoming increasingly attractive, highlighted by the development of Xian Janssen’s Balversa for patients harboring FGFR mutations, and are expected to gain approval during the forecast period, resulting in better treatment options for metastatic patients. Additionally, in view of the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter the bladder cancer market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable bladder cancer population, and how will drug-treatment rates change during the forecast period?·
- Which are the most commercially relevant drugs in China’s bladder cancer market and why? What are interviewed experts’ insights into current treatment options?·
- What are the market access considerations for key therapies in the bladder cancer pipeline in China? What sales could these agents secure in bladder cancer? What are interviewed experts’ opinions of key emerging therapies?·
- What are the key drivers and constraints in China’s bladder cancer therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release date
September 2021
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with hematologist-oncologists as well as 25 urologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology
Diagnosed incidence of bladder cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
FORECAST
Annualized, 10-year, drug-level sales and patient share of key bladder cancer therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III / PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I products.
